Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review
Open Access
- 20 May 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 24 (5) , 613-629
Abstract
This study aims to provide a comprehensive assessment of economic and health-related quality of life (HRQoL) outcomes for human epidermal growth factor receptor 2 (HER2)-positive, early-stage breast cancer patients treated with trastuzumab-containing regimens, by focusing on both Incremental Cost-Effectiveness Ratios (ICERs) and quality-adjusted life years (QALYs). A systematic search was conducted across PubMed, Embase, and Scopus databases without language or publication year restrictions. Two independent reviewers screened eligible studies, extracted data, and assessed methodology and reporting quality using the Drummond checklist and Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022), respectively. Costs were converted to US dollars (US$) for 2023 for cross-study comparison. Twenty-two articles, primarily from high-income countries (HICs), were included, with ICERs ranging from US$13,176/QALY to US$254,510/QALY, falling within country-specific cost-effectiveness thresholds. A notable association was observed between higher QALYs and lower ICERs, indicating a favorable cost-effectiveness and health outcome relationship. EQ-5D was the most utilized instrument for assessing health state utility values, with diverse targeted populations. Studies reporting higher QALYs tend to have lower ICERs, indicating a positive relationship between cost-effectiveness and health outcomes. However, challenges such as methodological heterogeneity and transparency in utility valuation persist, underscoring the need for standardized guidelines and collaborative efforts among stakeholders. PROSPERO ID: CRD42021259826.Keywords
Funding Information
- Indonesia Endowment Funds for Education (0005479/PHA/D/BUDI-2019)
This publication has 92 references indexed in Scilit:
- Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancerCancer, 2020
- Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomesBreast Cancer Research and Treatment, 2020
- The role of depression in the relationship between cognitive decline and quality of life among breast cancer patientsSupportive Care in Cancer, 2018
- Quality of life (QOL) and symptom burden (SB) in patients with breast cancerSupportive Care in Cancer, 2016
- The impact of cancer and quality of life among long-term survivors of breast cancer in AustriaSupportive Care in Cancer, 2016
- Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancerCancer, 2007
- Health related quality of life in different states of breast cancerQuality of Life Research, 2007
- Development of WHO guidelines on generalized cost-effectiveness analysisHealth Economics, 2000
- Methods for assessing relative importance in preference based outcome measuresQuality of Life Research, 1993
- Breast cancer screening and cost‐effectiveness; Policy alternatives, quality of life considerations and the possible impact of uncertain factorsInternational Journal of Cancer, 1991